Format

Send to

Choose Destination
Cancer Lett. 2010 Jan 1;287(1):13-22. doi: 10.1016/j.canlet.2009.05.008. Epub 2009 Jun 4.

Neopterin, a prognostic marker in human malignancies.

Author information

1
Center of Operative Medicine, Department of Visceral, Transplant, and Thoracic Surgery, Innsbruck Medical University, Austria.

Abstract

Increased neopterin concentrations are established in patients with an activated cellular (= Th1-type) immune response which includes allograft rejection, viral infection and autoimmune disorders as well as various malignant tumors. In patients with several types of cancer, neopterin concentrations in body fluids like urine, serum/plasma or ascites parallel the course of the disease, and a higher neopterin concentration in patients is an independent predictor of a shorter survival period. Neopterin is released in large amounts from human monocyte-derived macrophages and dendritic cells preferentially following stimulation with the pro-inflammatory cytokine interferon-gamma, thus reflecting the immune activation status. Therefore, not only as a laboratory diagnostic tool, the measurement of neopterin concentrations allows studying the immunological network and its interaction with the pathogenesis of tumor development. It contributes to a better understanding how immune activation is involved in the development of tumor-induced immune escape and tumor antigen specific tolerance.

PMID:
19500901
DOI:
10.1016/j.canlet.2009.05.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center